Crystalline forms of a Bruton's tyrosine kinase inhibitor

  • US 10,294,231 B2
  • Filed: 08/23/2018
  • Issued: 05/21/2019
  • Est. Priority Date: 06/04/2012
  • Status: Active Grant
First Claim
Patent Images

1. A pharmaceutical formulation for oral administration comprising:

  • (a) about 40 mg to about 200 mg of 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one;

    (b) about 40 wt % to about 50 wt % of one or more diluents;

    (c) about 3 wt % to about 10 wt % of one or more disintegrating agents;

    (d) about 2 wt % to about 7 wt % of one or more surfactants; and

    (e) one or more lubricants.

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×